NCT02496988

Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas

A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: The First People's Hospital of Changzhou · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Advanced Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.

Conditions

• Cytokine-Induced Killer Cells
• Advanced Milignant Gliomas

Interventions

Type	Name	Description
DRUG	Temozolomide	Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
BIOLOGICAL	CIK	The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat

Timeline

• Start date: 2015-07-01
• Primary completion: 2028-07-01
• Completion: 2030-07-01
• First posted: 2015-07-14
• Last updated: 2015-07-14